Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL

Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL

Although prostate-specific antigen (PSA) is a very useful screening tool, prostate biopsy is still necessary to confirm prostate cancer (PCA). However, it is reported that PSA is associated with a high false-positive rate and prostate biopsy also has various procedure-related complications. Therefor...

Full description

Bibliographic Details
Main Authors:	Ahn, Jae Hyun, Lee, Jeong Zoo, Chung, Moon Kee, Ha, Hong Koo
Format:	Online
Language:	English
Published:	The Korean Academy of Medical Sciences 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945127/

Similar Items

Predictive Factors for Prostate Cancer in Biopsy of Patients with Prostate-Specific Antigen Levels Equal to or Less Than 4 ng/ml
by: Kim, Hyoung Woo, et al.
Published: (2011)

Prostate-Specific Antigen Density as a Powerful Predictor of Extracapsular Extension and Positive Surgical Margin in Radical Prostatectomy Patients with Prostate-Specific Antigen Levels of Less than 10 ng/ml
by: Chang, Jin-Seok, et al.
Published: (2011)

Prostate Cancer Can Be Detected Even in Patients with Decreased PSA Less than 2.5 ng/ml after Treatment of Chronic Prostatitis
by: Kim, Young Jung, et al.
Published: (2011)

Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10 ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease?
by: Taverna, Gianluigi, et al.
Published: (2012)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
by: LIU, Xin, et al.
Published: (2015)

Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL
by: Lee, Dong Hoon, et al.
Published: (2016)

Clinical Significance of Free-to-Total Prostate-Specific Antigen (PSA) Ratio in Advanced Prostate Cancer Patients with PSA Less than 0.1 ng/ml after Hormone Treatment
by: Kim, Dae Il, et al.
Published: (2012)

Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml
by: Wang, Xuan, et al.
Published: (2016)

Effect of Transurethral Resection of the Prostate on Storage Symptoms in Patients with Benign Prostatic Hyperplasia of Less than 30 ml
by: Kang, Yu Jin, et al.
Published: (2013)

Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10–20 ng/mL and normal digital rectal examination
by: Chiu, Peter Ka-Fung, et al.
Published: (2016)

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml−1
by: Chen, Rui, et al.
Published: (2015)

Impact of Real-Time Elastography versus Systematic Prostate Biopsy Method on Cancer Detection Rate in Men with a Serum Prostate-Specific Antigen between 2.5 and 10 ng/mL
by: Taverna, Gianluigi, et al.
Published: (2013)

AB013. The study on the diagnostic value of f/tPSA to the prostate cancer with tPSA greater than 10 ng/mL
by: Li, Yan-Feng, et al.
Published: (2016)

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml
by: Ferro, Matteo, et al.
Published: (2013)

Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml
by: Umezawa, Rei, et al.
Published: (2011)

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
by: Lee, Seung Hwan, et al.
Published: (2011)

Efficacy of Repeated Transrectal Prostate Biopsy in Men Younger Than 50 Years With an Elevated Prostate-Specific Antigen Concentration (>3.0 ng/mL): Risks and Benefits Based on Biopsy Results and Follow-up Status
by: Park, Ho Gyun, et al.
Published: (2014)

The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0–10.0 ng/mL) in Nigeria
by: Ezenwa, E.V., et al.
Published: (2012)

Editorial comment to “The value of percentage free prostate-specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0–10.0 ng/mL) in Nigeria” and Reply by authors
by: Elabbady, Ahmed, et al.
Published: (2012)

The association of markers of oxidative-inflammatory status with malnutrition in hemodialysis patients with serum ferritin lower than 500 ng/mL
by: Simone Gonçalves de Almeida, et al.
Published: (2013-03-01)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml
by: Chen, Rui, et al.
Published: (2015)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
by: Busato, W. F. S., et al.
Published: (2015)

A pilot study on the use of serum glyoxalase as a supplemental biomarker to predict malignant cases of the prostate in the PSA range of 4-20 ng/ml
by: Chavan, Sushant V., et al.
Published: (2011)

The use of nomograms in LDR-HDR prostate brachytherapy
by: Pujades, Ma Carmen, et al.
Published: (2011)

External validation of extended prostate biopsy nomogram
by: Hrbáček, Jan, et al.
Published: (2015)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml-1 and 10.1–20.0 ng ml-1: a multicenter study
by: Lin, Yu-Rong, et al.
Published: (2015)

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL
by: Takeshi Kashiwabara, et al.
Published: (2018-05-01)

AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score
by: Fang, Dong, et al.
Published: (2016)

Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score
by: Fang, Dong, et al.
Published: (2015)

Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
by: Fiamegos, Alexandros, et al.
Published: (2016)

Letter to the Editor: Vienna Nomogram-Based Prostate Biopsy: Can It Be a Much Better Diagnostic Tool Than Other Conventional Prostate Biopsies?
by: Ho, Christopher Chee Kong, et al.
Published: (2014)

Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation
by: Kalaitzis, Christos, et al.
Published: (2014)

Impact of Comorbidity, Race, and Marital Status in Men Referred for Prostate Biopsy with PSA >20 ng/mL: A Pilot Study in High-Risk Patients
by: Klaassen, Zachary, et al.
Published: (2014)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
by: Ku, Ja Yoon, et al.
Published: (2015)

Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study
by: Liu, Hsin-Ho, et al.
Published: (2016)

External Validation of an Artificial Neural Network and Two Nomograms for Prostate Cancer Detection
by: Ecke, Thorsten H., et al.
Published: (2012)

Detection Rate of Prostate Cancer on the Basis of the Vienna Nomogram: A Singapore Study
by: Teo, Jin Kiat, et al.
Published: (2014)

A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes
by: Wu, Raymond, et al.
Published: (2015)

Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer
by: Miyoshi, Yasuhide, et al.
Published: (2015)

Development and external validation of a prostate health index-based nomogram for predicting prostate cancer
by: Zhu, Yao, et al.
Published: (2015)